Belkin Announces Mobile Charging Accessories That Are Made-to-Move and New Ways to Protect and Connect Devices
5.9.2024 10:00:00 CEST | Business Wire | Press release
Belkin International at Exhibit Hall 3.2, stand #210
Belkin, a leading consumer electronics brand for over 40 years, today announced 11 new travel-ready products across its mobile charging category, as well as solutions to enable more flexible options to work while on the go. Designed in California at its in-house labs, the new announcements underscore Belkin innovation, quality and its commitment to building products consumers need. All new products are made with post-consumer recycled (PCR) plastics in line with the company’s commitment to find more responsible ways to build products.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240905171274/en/
Belkin announces new BoostCharge collection at IFA 2024 (Photo: Business Wire)
Belkin International can be found on the IFA show floor, Exhibit Hall 3.2, stand #210.
Foldable Wireless Chargers with Qi2
BoostCharge Magnetic Foldable Charger
This folding stand design is compact and travel ready. Delivering 15W of fast wireless charging to iPhone and other Qi2 enabled devices, its powerful magnetic connection secures the device to charging stand and magnetically holds it vertically or horizontally for hands-free use. Use the elevated, customizable position to scroll or watch, and support the Standby Mode feature for iPhone users. It is available in two versions: standalone charges phone only; the 2-in-1 version charges phone and earbuds. 20W power supply and USB-C cable are included. Premium materials include soft touch phone pad, non-slip base and durable hinge construction.
Price: $44.99 / £39.99 / €44.99 to $69.99 / £59.99 / €69.99
Availability: Standalone version coming September 2024; 2-in-1 version available now at belkin.com and available from Autumn 2024 in select retailers worldwide.
BoostCharge 3-in-1 Magnetic Foldable Charger
Charge all your essentials with this foldable 3-in-1. Both portable and with customizable charging angles, it delivers 15W of fast wireless charging to iPhone or Qi2 enabled device, 5W to Apple Watch and 5W for earbuds. If used as a pad, keep it flat. If a stand is preferred, the pad lifts easily and holds steady. Simply fold it down for safe transport when it’s time to pack it away.
Price: $99.99 / £99.99 / €99.99
Availability: Available now at belkin.com and select retailers worldwide.
BoostCharge Pro Magnetic Wireless Travel Pad
A traveller’s best friend. Available in both 2-in-1 and 3-in-1 versions, use it as a pad or fold up into a stand. It delivers 15W of fast wireless charging to iPhone or Qi2 enabled device, 5W to Apple Watch and 5W for earbuds. Qi2 magnetic technology means the phone is held secure, optimizing energy usage and safeguarding the device's battery life.
Price: $119.00 / £109.00 / €119.00 to $129.99 / £119.99 / €129.99
Availability: Coming Autumn 2024 to belkin.com and select retailers worldwide.
High-capacityPower Banks
BoostCharge Power Bank 10K w/ Integrated Cable
This compact 10K power bank makes charging easy. With integrated PD PPS, charge a USB-C smartphone, earbuds or tablet. It provides the option to split the power and charge multiple devices at once. Available in Black, Blue and Pink and White (MEA exclusive).
Price: $39.99 / £24.99 / €29.99
Availability: Coming Autumn 2024 to belkin.com and select retailers worldwide.
BoostCharge Pro 3-Port Laptop Power Bank 20K
This 65W power bank is built with a 20K battery capacity; enough to charge a laptop, MacBook or smartphone quickly and safely. Its full colour digital display shows battery status to easily monitor the remaining charge and manage power needs efficiently for all devices. Options for 65W PD via single USB-C connection or split the power across two USB-Cs and a USB-A, to charge 3 devices simultaneously.
Price: $89.99 / £79.99 / €89.99
Availability: Available now at belkin.com and belkin.com/uk, and coming soon to select retailers worldwide.
Cables Made More Responsibly
BoostCharge 2-in-1 USB-C and Lightning Cable
Charge existing and future devices with this 2-in-1 cable. MFi and USB-IF certified and tested to over 30,000 bends and over 10,000 plug-ins, this cable will deliver up to 60W of power to any USB-C or Lightning device. It features a built-in interchangeable Lightning connector for users to easily switch between their charging needs. A handy cable strap keeps things tidy and protects it from tangles. Exterior braiding is made of 100% post-consumer recycled polyester, certified by the Global Recycled Standard (GRS), cable head and internal jacket are made of 50% GRS-certified post-consumer recycled thermoplastic.
This is part of a rolling change to transition all our PVC and Braided PVC to PCR material.
Price: $24.99 / £19.99 / €24.99
Availability: Coming Autumn 2024 to select retailers worldwide.
Portable Keyboards for Work-on-the-go
Pro Keyboard Case collection
The Belkin Pro Keyboard case makes working from anywhere, easy. The backlit Bluetooth keyboard pairs to iPad to offer the ease of use of an external keyboard with the added defence of a protective cover. The premium faux leather exterior protects the device, while a soft, anti-slip interior protects the screen from scratches. It auto wakes/sleeps when opening/closing, and features a large, click-anywhere trackpad. Its long-lasting battery (between 460mAh – 600mAh) holds charge independently from iPad.
- Everyday Keyboard Case with Cradle for iPad Air 10.9" and iPad Pro 11" £99.99/ €109.99
- Pro Keyboard Case with Magnetic Stand for iPad Air 10.9" and iPad Pro 11"£139.99 / €149.99
- Pro Keyboard Case with Magnetic Stand for iPad Pro 12.9"£189.99 / €199.99
Availability: Available now at belkin.com/uk,belkin.com/de and Belkin EMEA retailers.
Media kit is available for download HERE.
About Belkin
Belkin is a California-based accessories leader delivering award-winning power, protection, productivity, connectivity, and audio products over the last 40 years. Designed and engineered in Southern California and sold in more than 100 countries around the world, Belkin has maintained its steadfast focus on research and development, community, education, sustainability and most importantly, the people it serves. From our humble beginnings in a Southern California garage in 1983, Belkin has become a diverse, global technology company. We remain forever inspired by the planet we live on, and the connection between people and technology.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240905171274/en/
Contacts
For Media Inquiries:
For Media Inquiries:
Jen Wei
VP of Global Communications and Corporate Development
Comms@belkin.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom